^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastrointestinal Cancer

    15h
    TARLANEC: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (clinicaltrials.gov)
    P3, N=129, Recruiting, Intergroupe Francophone de Cancerologie Thoracique | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Aug 2030 | Initiation date: Sep 2025 --> Feb 2026 | Trial primary completion date: Sep 2028 --> Feb 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    docetaxel • 5-fluorouracil • irinotecan • Imdelltra (tarlatamab-dlle)
    1d
    Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, University of Oklahoma | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date • Checkpoint inhibition
    2d
    Nucleotide salvage, genome instability, and potential therapeutic applications. (PubMed, Nucleic Acids Res)
    Emerging evidence links salvage metabolism to tumor progression, where incorporation of salvage-derived nucleotides may contribute to unexplainable mutational signatures detected in cancers, such as gastrointestinal cancer. Recognizing salvage as a hidden source of mutagenesis reshapes our understanding of genome instability and provides potential opportunities for disease prevention, diagnosis, and therapeutic intervention.
    Review • Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    2d
    Gastrointestinal Stromal Tumors: Histopathological Spectrum, Molecular Subtypes, and Implications for Targeted Therapy. (PubMed, Cureus)
    Targeted tyrosine kinase inhibitors (TKIs) have transformed GIST management, with imatinib as the foundational first-line therapy and subsequent agents, sunitinib, regorafenib, avapritinib, and ripretinib, addressing primary or secondary resistance driven by diverse mutational patterns. Emerging therapeutic directions include next-generation kinase inhibitors, heat shock protein inhibitors, immunotherapy, metabolic and epigenetic targeting, and biomarker-driven individualized treatment strategies. This review synthesizes contemporary advances in the histopathological, molecular, and therapeutic landscape of GISTs, emphasizing an integrated diagnostic approach and highlighting ongoing efforts to overcome therapeutic resistance and optimize personalized care.
    Review • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • CD34 (CD34 molecule) • NTRK (Neurotrophic receptor tyrosine kinase) • ANO1 (Anoctamin 1)
    |
    KRAS mutation • BRAF mutation • KIT mutation • PDGFRA D842V • PDGFRA mutation • NTRK fusion
    |
    imatinib • sunitinib • Stivarga (regorafenib) • Ayvakit (avapritinib) • Qinlock (ripretinib)
    3d
    Gastric Adenocarcinoma With Enteroblastic Differentiation Presenting as Lung Nodules: A Diagnostic Dilemma. (PubMed, J Community Hosp Intern Med Perspect)
    The patient was started on capecitabine and oxaliplatin in addition to trastuzumab with subsequent clinical and radiological improvement. Unresectable, metastatic HER2 positive conventional adenocarcinoma is being managed using platinum-fluoropyrimidine doublet therapy with anti-HER2 monoclonal antibody trastuzumab. This case report calls for aggressive IHC staining for prompt diagnosis where necessary as well as proper guidelines for management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • CDX2 (Caudal Type Homeobox 2) • SALL4 (Spalt Like Transcription Factor 4) • TCF4 (Transcription Factor 4)
    |
    PD-L1 expression • HER-2 positive • TP53 mutation • HER-2 expression • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab) • capecitabine • oxaliplatin
    4d
    cGAS-STING Pathway in Gastrointestinal Malignancies: Mechanistic Insights and Translational Therapeutic Opportunities. (PubMed, J Gastrointest Cancer)
    This review consolidates current mechanistic insights, preclinical evidence, and emergent clinical data regarding the cGAS-STING pathway in gastrointestinal cancers, while emphasising biomarker-guided patient stratification and AI-powered predictive tools that could facilitate the precise application of STING-targeted therapies.
    Review • Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase)
    5d
    VEINOPAN: Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=40, Completed, University Hospital, Rouen | Recruiting --> Completed | N=30 --> 40 | Trial completion date: Apr 2026 --> Oct 2025 | Trial primary completion date: Apr 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    5d
    A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) (clinicaltrials.gov)
    P1, N=17, Terminated, Peking University | N=42 --> 17 | Trial completion date: Mar 2028 --> Oct 2025 | Recruiting --> Terminated; achieved the proof of concept
    Enrollment change • Trial completion date • Trial termination
    |
    cyclophosphamide • fludarabine IV
    6d
    INCISIVE: Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer (clinicaltrials.gov)
    P3, N=207, Completed, University Hospital, Rouen | Unknown status --> Completed | N=754 --> 207
    Trial completion • Enrollment change
    6d
    TIER-PC: Tier Palliative Care For Patients With Advanced Heart Failure or Cancer (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Icahn School of Medicine at Mount Sinai
    New trial
    6d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jun 2025 --> Feb 2026
    Trial initiation date
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    6d
    Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies. (PubMed, ESMO Gastrointest Oncol)
    Therapeutic targeting of BRAFV600E has led to the approval of dabrafenib plus trametinib for solid tumours [excluding colorectal cancer (CRC)] refractory to standard therapies...In CRC, intrinsic epidermal growth factor receptor (EGFR) activation circumvents BRAF inhibition, necessitating the concurrent use of EGFR inhibitors, whose treatment strategy led to the approval of encorafenib plus cetuximab for BRAF V600E CRC...While noteworthy results have been achieved with BRAFV600E inhibition, further research is needed to optimize BRAF-targeted therapies and address resistance mechanisms. Continued research and innovation are crucial to improving patient outcomes and addressing the complexities of BRAF mutations in human cancers.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • EGFR mutation
    |
    Erbitux (cetuximab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Braftovi (encorafenib)